Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma

Harda, Kristóf; Szabó, Zsuzsanna; Szabó, Erzsébet; Oláh, Gábor; Fodor, Klara; Szász, Csaba; Méhes, Gábor; Halmos, Gábor

doi:10.3390/molecules23071535

Cited by 4 publications

(3 citation statements)

References 59 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from Hungary in 2018 used RT-PCR, a ligand-binding assay, and Western blot [ 53 ] analysis to study SSTR expression and mRNA transcript levels in 46 specimens of human uveal melanoma. SSTR expression was noted in 70% of specimens.…”

Section: Resultsmentioning

confidence: 99%

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review

2022

View full text Add to dashboard Cite

Somatostatin receptors (SSTR) are expressed in various neoplasms and can be targeted for both diagnostics as well as therapeutics. This systematic review aims to compile and discuss the prevalence of somatostatin receptor expression in various neoplasms. We performed a literature search from Google Scholar and PubMed using relevant keywords to look for all publicly available data regarding SSTR expression in various cancers. Both histopathological and radiographical studies were included for SSTR assessment. We found that many cancers express SSTR with varying prevalence. SSTR is now a well-established theranostics biomarker. We now have highly sensitive and specific diagnostic modalities like gallium 68 DOTATATE and copper 64 DOTATATE scans to screen for SSTR-2 and then target it therapeutically with lutetium 177 DOTATATE. A thorough understanding of SSTR expression in other tumors will open the channels for exploring potential SSTR targeting.

show abstract

Section: Resultsmentioning

confidence: 99%

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review

2022

View full text Add to dashboard Cite

show abstract

“…The possible use of somatostatin receptors as molecular targets in anticancer therapy was also explored in uveal melanoma, which expresses mostly SSTR-2 and SSTR-5 [ 214 ]. While the use of somatostatin analogs was proposed as a potential therapy, their impact is undetermined, and there is no consensus regarding the role of SSTRs as prognostic markers in uveal melanoma [ 215 , 216 ].…”

Section: Neurohormones and Melanomamentioning

confidence: 99%

Neuroendocrine Factors in Melanoma Pathogenesis

Scheau

Drăghici

Ilie

et al. 2021

Cancers

View full text Add to dashboard Cite

Melanoma is one of the most aggressive skin cancers with a sharp rise in incidence in the last decades, especially in young people. Recognized as a significant public health issue, melanoma is studied with increasing interest as new discoveries in molecular signaling and receptor modulation unlock innovative treatment options. Stress exposure is recognized as an important component in the immune-inflammatory interplay that can alter the progression of melanoma by regulating the release of neuroendocrine factors. Various neurotransmitters, such as catecholamines, glutamate, serotonin, or cannabinoids have also been assessed in experimental studies for their involvement in the biology of melanoma. Alpha-MSH and other neurohormones, as well as neuropeptides including substance P, CGRP, enkephalin, beta-endorphin, and even cellular and molecular agents (mast cells and nitric oxide, respectively), have all been implicated as potential factors in the development, growth, invasion, and dissemination of melanoma in a variety of in vitro and in vivo studies. In this review, we provide an overview of current evidence regarding the intricate effects of neuroendocrine factors in melanoma, including data reported in recent clinical trials, exploring the mechanisms involved, signaling pathways, and the recorded range of effects.

show abstract

“…Somatostatin receptors (SSTR) are membrane-bound G-proteins that mediate physiological functions of somatostatin in the body [1]. Overexpression of SSTR has been found in pituitary adenomas (PA) and many human malignancies including lung, breast, and prostate cancers, colon carcinoma, glioblastoma, and uveal melanoma [2][3][4][5][6][7][8][9][10][11]. SSTR are divided into five basic subtypes: SSTR-1 (SSTR-1 gene location 14q13), SSTR-2 (17q24), SSTR-3 (22q13.1), SSTR-4 (20p11.2), and SSTR-5 (16p13.3).…”

Section: Introductionmentioning

confidence: 99%

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

Hematological and oncological disorders represent leading causes of childhood mortality. Neuropeptide somatostatin (SST) has been previously demonstrated in various pediatric tumors, but limited information exists on the expression and characteristics of SST receptors (SSTR) in hematological and oncological disorders of children. We aimed to investigate the expression of mRNA for SSTR subtypes (SSTR-1–5) in 15 pediatric hematological/oncological specimens by RT-PCR. The presence and binding characteristics of SSTRs were further studies by ligand competition assay. Our results show that the pediatric tumor samples highly expressed mRNA for the five SSTR subtypes with various patterns. The mRNA for SSTR-2 was detected in all specimens independently of their histological type. A Hodgkin lymphoma sample co-expressed mRNA for all five SSTR subtypes. SSTR-3 and SSTR-5 were detected only in malignant specimens, such as rhabdomyosarcoma, Hodgkin lymphoma, acute lymphoblastic leukemia, and a single nonmalignant condition, hereditary spherocytosis. The incidence of SSTR-1 and SSTR-4 was similar (60%) in the 15 specimens investigated. Radioligand binding studies demonstrated the presence of specific SSTRs and high affinity binding of SST analogs in pediatric solid tumors investigated. The high incidence of SSTRs in hematological and oncological disorders in children supports the merit of further investigation of SSTRs as molecular targets for diagnosis and therapy.

show abstract

Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma

Cited by 4 publications

References 59 publications

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review

Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review

Neuroendocrine Factors in Melanoma Pathogenesis

Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders

Contact Info

Product

Resources

About